Piper Sandler Maintains Overweight on Acrivon Therapeutics, Raises Price Target to $8
Benzinga Newsdesk 9 months ago
NewsPrice TargetAnalyst Ratings
Piper Sandler analyst Edward Tenthoff maintains Acrivon Therapeutics (NASDAQ:ACRV) with a Overweight and raises the price target from $6 to $8.
Piper Sandler analyst Edward Tenthoff maintains Acrivon Therapeutics (NASDAQ:ACRV) with a Overweight and raises the price target from $6 to $8.